Media
Here in the media centre you will find a range of resources including our latest and archived press releases, statements from our CEO, speeches and presentations, information on our social media policy, and our photo and video library.
Find the latest and archived speeches and presentations from GSK’s senior executives.
Press releases
GSK statement regarding 2010 Nature Medicine study
GSK and Nature Medicine recently became aware of allegations of misrepresentation of data in a research paper written by scientists at GSK’s China research centre and published in Nature Medicine in 2010.
GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)
GlaxoSmithKline [NYSE: GSK] confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to continue to make Avandia (rosiglitazone) available to appropriate patients with the majority of the members voting to either modify (13) or remove (7) the Risk Evaluation and Mitigation Strategy (REMS) program in place. Remaining members voted to continue the REMS (5) or withdraw (1) Avandia from the US market.
GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer
GlaxoSmithKline (GSK) plc today announced that its study of TYKERB/TYVERB® (lapatinib) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary endpoint of improved overall survival (OS) compared to chemotherapy alone.
